Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy.
Hainsworth, John D
Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy. [electronic resource] - Breast cancer research and treatment 11 2016 - 41-49 p. digital
Publication Type: Journal Article
1573-7217
10.1007/s10549-016-3969-7 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological--pharmacology
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor
Breast Neoplasms--diagnosis
Drug Resistance, Neoplasm--genetics
Female
Gene Expression
Humans
Immunoassay--methods
Middle Aged
Models, Biological
Molecular Targeted Therapy
Neoplasm Metastasis
Neoplasm Staging
Neoplastic Cells, Circulating--metabolism
Receptor, ErbB-2--antagonists & inhibitors
Retreatment
Signal Transduction--drug effects
Treatment Outcome
Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy. [electronic resource] - Breast cancer research and treatment 11 2016 - 41-49 p. digital
Publication Type: Journal Article
1573-7217
10.1007/s10549-016-3969-7 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological--pharmacology
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor
Breast Neoplasms--diagnosis
Drug Resistance, Neoplasm--genetics
Female
Gene Expression
Humans
Immunoassay--methods
Middle Aged
Models, Biological
Molecular Targeted Therapy
Neoplasm Metastasis
Neoplasm Staging
Neoplastic Cells, Circulating--metabolism
Receptor, ErbB-2--antagonists & inhibitors
Retreatment
Signal Transduction--drug effects
Treatment Outcome